Nov 2021: Det første kliniske forsøg med Sydkoreas hjemmedyrkede næste generation af kimærisk antigenreceptor T (CAR-T) celleterapi, som er designet til at omgå signaler fra immunkontrolpunkter, er for nylig gået i gang.
Korea Advanced Institute of Science and Technology (KAIST) meddelte onsdag, at et fase 1b klinisk forsøg med dets CAR-T-celleterapi i øjeblikket udføres på Samsung Medical Center i Seoul. Forsøget udføres med 10 koreanske patienter, som har recidiverende og refraktær diffust storcellet B-celle lymfom. Markedsføringsrettighederne til pipelinen blev overført fra universitetet til virksomheden Curocell, som var medstiftet af professor Kim Chan-hyuk. Curocell er ansvarlig for den revolutionæres kliniske udviklingsprogram immunterapi.
In addition, a Phase 2 kliniske forsøg involving seventy participants is going to take place the following year to assess how safe and effective the investigational medication is.
The acronym CAR T, which stands for kimær antigenreceptor T, is frequently referred to as a miracle cure. This is due to the fact that studies conducted in other countries on terminal blood cancer patients demonstrated that the therapy had a therapeutic effect of more than 80 percent. T cells from a patient are taken from the patient’s blood, genetically enhanced to make them more effective, and then reintroduced to the patient so that they can continue to fight and destroy cancer cells inside the patient’s body.
The research team that was led by Professor Kim of the Department of Biomedical Engineering at the KAIST confirmed an improved anticancer efficacy of CAR-T cells in mice with leukaemia and lymphoma. This was achieved by simultaneously inhibiting programmed cell death protein 1 (PD-1) and T-cell immunoglobulin and ITIM domain (TIGIT), both of which are known to disturb the function of T cells. According to Professor Lee Young-ho, a post-doctoral researcher at KAIST and the first author of the animal model study, this dual blockade of PD-1 and TIGIT is a novel strategy to overcome the immunosuppression of existing CAR-T cells. This strategy was discovered by Prof. Lee Young-ho.
Du kan godt lide at læse: CAR T-Cell terapi i Korea
Resultaterne af undersøgelsen blev præsenteret i en artikel, der blev offentliggjort online i oktoberudgaven af Molecular Therapy.
